DEF 14A: Quoin Pharmaceuticals Seeks Shareholder Approval for Director Elections, Compensation Programs, and Charter Amendments at Upcoming Annual Meeting

Quoin Pharmaceuticals is holding its Annual General Meeting on December 5, 2024, to vote on director elections, executive compensation, amendments to the Articles of Association, and appointment of an independent auditor.

Summary

• Quoin Pharmaceuticals Ltd. is holding its 2024 Annual General Meeting of Shareholders on December 5, 2024, in Philadelphia.
• Shareholders will vote on seven proposals, including the election of directors, amendments to the company's Articles of Association, approval of compensation programs for the CEO and COO, changes to the non-employee director compensation program, appointment of Marcum LLP as the independent auditor, and approval of the CEO serving as Chairman of the Board for another three years.
• The Board of Directors recommends voting FOR all seven proposals.
• The record date for determining shareholders eligible to vote is October 21, 2024.
• A quorum of at least two shareholders holding at least 25% of the outstanding voting rights is required to convene the meeting.
• The approval of each proposal requires the affirmative vote of the holders of a majority of the shares that are voted in person or by proxy on such proposal at the Annual Meeting, with abstentions not taken into account for voting purposes.
• Proposals 3, 4, and 7 require a special majority vote, excluding votes from controlling shareholders or those with a personal interest, or ensuring that opposing votes do not exceed 2% of the total voting rights.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral and informative tone. The Board's recommendations are positive, but the overall sentiment is balanced and objective.

Positives

• The proposed amendments to the Articles of Association aim to align the company's governance with current Israeli regulations.
• The proposed compensation programs for the CEO and COO are designed to incentivize and retain key executives.
• The proposed changes to the non-employee directors' compensation program are intended to attract and retain qualified board members.
• The reappointment of Marcum LLP as the independent auditor provides continuity and expertise in financial oversight.

Risks

• Failure to achieve the required quorum could result in adjournment of the Annual Meeting.
• If shareholders do not approve the compensation programs for the CEO and COO, it could impact the company's ability to retain these key executives.
• If shareholders do not approve Dr. Myers serving as both CEO and Chairman, the board has appointed Dr. Dennis Langer to assume the role of Interim Chairman until such time as the Company's shareholders may approve Dr. Myers reappointment as Chairman of the Board.

Future Outlook

The document outlines proposals for the future governance and management of the company, including director elections, executive compensation, and structural changes to the Articles of Association.

Management Comments

• Dr. Michael Myers, Chairman of the Board and Chief Executive Officer, urges shareholders to vote by marking, signing, and dating the proxy card or voting instruction form and returning it promptly.
• The Board recommends that the shareholders vote FOR Proposals 1-7 as described in the accompanying proxy statement.

Industry Context

This announcement is a standard corporate governance procedure for publicly traded companies, ensuring shareholder participation in key decisions regarding the company's direction and leadership.

Comparison to Industry Standards

• The proposals regarding director elections, executive compensation, and auditor appointment are typical agenda items for annual general meetings of publicly traded companies.
• The proposed amendments to the Articles of Association reflect an effort to align with current Israeli regulations, which is a common practice for companies incorporated in Israel.
• The compensation levels for executives and non-employee directors are likely benchmarked against peer companies in the pharmaceutical industry to ensure competitiveness.

Corporate Governance

Related Party Transactions

• During the year ended December 31, 2021, Quoin Inc. paid $100,000 of consulting expenses to a company controlled by Dennis Langer, our director.
• Approximately $8,000, $48,000 and $12,000 were paid during the years ended December 31, 2021, 2022 and 2023, respectively, to Dr. Myers son, who was consulting Quoin Inc. on research and development matters from time to time.
• Due to the limited funding of Quoin Inc. prior to the consummation of the Business Combination, the compensation, including salary, office and car allowances and other benefits, due to Dr. Myers and Ms. Carter under their respective employment agreements, as well as reimbursement of expenses and other amounts paid by Dr. Myers and Ms. Carter to third parties on behalf of Quoin Inc., were not paid by Quoin Inc. to Dr. Myers and Ms. Carter, and were accrued as indebtedness to Dr. Myers and Ms. Carter.
• Commencing in October 2020, Quoin Inc. issued promissory notes (the 2020 Notes) to five noteholders, including our directors, Messrs. Langer and Culverwell (collectively, 2020 Noteholders).

Stakeholder Impact

• Shareholders have the opportunity to influence the company's direction through voting on key proposals.
• Employees may be affected by changes in executive compensation and company strategy.
• The company's financial performance and governance practices can impact investor confidence and stock price.

Next Steps

• Shareholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual General Meeting on December 5, 2024.
• The company will announce the results of the shareholder vote in a Current Report on Form 8-K.

Key Dates

Keywords

Annual General Meeting, Proxy Statement, Shareholders, Directors, Compensation, Articles of Association, Marcum LLP, Corporate Governance, Quoin Pharmaceuticals